2.Benign Cephalic Histiocytosis in a Patient with Neurofibromatosis Type 1
Min Jung KWON ; Jung Eun KIM ; Young Lip PARK ; SangHoon LEE ; Sul Hee LEE
Korean Journal of Dermatology 2023;61(8):513-517
Benign cephalic histiocytosis (BCH) is an uncommon subtype of non-Langerhans cell histiocytosis. A 5-month-old boy presented with multiple yellowish facial papules and plaques, which later spread to his trunk and both extremities. Laboratory tests, including lipid profile, were normal. Histological examination revealed non-foamy histiocytes, lymphocytes, and some eosinophils in the dermis. Immunohistochemical staining was positive for CD68and factor XIIIa, but negative for CD1a and S-100. Additionally, the patient developed multiple café-au-lait spots with axillary and inguinal freckling. Next-generation sequencing identified a pathogenic variant of the neurofibromatosis type 1 (NF1) gene. Herein, we report a rare case of BCH in a patient with NF1. Although many cases of NF1 accompanied by juvenile xanthogranuloma have been reported, the association between BCH and NF1 has not been elucidated. However, considering that BCH may be a clinicopathological variant of juvenile xanthogranuloma, an association between the two diseases can be considered.
4.Expression of Antioxidant Response and Autophagy Markers in Patients with Vitiligo:An Immunohistochemical Study
Eun Ji HONG ; Hee Jung YOON ; Ryung KWON ; Young Lip PARK ; Sul Hee LEE ; SangHoon LEE
Korean Journal of Dermatology 2023;61(2):79-85
Background:
Oxidative stress is generally accepted as one of the principal pathogenesis of vitiligo, and keratinocyte-melanocyte interactions are also thought to play critical roles. It is well-known that antioxidant response and autophagy protect cells against oxidative damage, but the details and the compensatory relationship between the two mechanisms in the keratinocytes of vitiligo lesions remain unclear.
Objective:
To evaluate the antioxidant response and autophagy status of patients with vitiligo and to explore the interactions between these two mechanisms.
Methods:
Ten patients with clinicopathologically proven vitiligo and 10 normal controls were enrolled in our Department of Dermatology, Soonchunhyang University Hospital, Bucheon, Korea. Tissue samples of vitiligo lesions in the patient group and normal skin in the control group were immunohistochemically stained for nuclear factor erythroid 2-related factor 2 (Nrf2), Beclin-1, microtubule-associated protein light chain 3 (LC3)-II, and p62. The immunopositivity of epidermal keratinocytes was evaluated.
Results:
Keratinocytes in vitiligo lesions had a significantly lower expression of Nrf2 (p=0.002) than that in the cells of normal controls. The levels of autophagy markers did not differ significantly between the two groups, but decreases in the Beclin-1 and LC3-II levels, and an increase in the p62 level in the patient group may indicate a small decrease in autophagy of patients with vitiligo.
Conclusion
Decreased antioxidant response and reduced autophagy may trigger melanocyte apoptosis in vitiligo lesions.
5.A Case of Multiple Miliary Osteoma Cutis on the Face of Middle-Aged Woman after Injection of Unspecified Filler Material
Hee Jung YOON ; Eun Ji HONG ; Jung Eun KIM ; Young Lip PARK ; SangHoon LEE ; Sul Hee LEE
Korean Journal of Dermatology 2023;61(3):194-198
Multiple miliary osteoma cutis (MMOC) is a rare variant of osteoma, characterized by multiple eruptive hard nodules on the face. A 70-year-old female presented with multiple solid skin-colored papules on both cheeks, unresponsive to conventional medical treatments. She reported receiving an injection of an unknown cosmetic filler substance into her face by an unlicensed medical practitioner 20 years ago. Facial computed tomography showed multiple small calcifications immediately adjacent to foreign material assumed to be the filler substance in the dermis. Histological examination revealed osteoclasts, osteocytes, and eosinophilic bony tissue in the dermis, suggestive of osteoma cutis. Although the pathogenesis remains unclear, inflammation caused by injected foreign material may induce metaplastic transformation of multipotent mesenchymal cells into osteoblasts, resulting in heterotopic ossification. Dermatologists should be aware that MMOC may occur following injection of foreign material by unlicensed practitioners. Performing a detailed history and clinical evaluation may aid in the diagnosis of such recalcitrant skin lesions.
6.Erratum: Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea
Sang Wook SON ; Ji Hyun LEE ; Jiyoung AHN ; Sung Eun CHANG ; Eung Ho CHOI ; Tae Young HAN ; Yong Hyun JANG ; Hye One KIM ; Moon-Bum KIM ; You Chan KIM ; Hyun Chang KO ; Joo Yeon KO ; Sang Eun LEE ; Yang Won LEE ; Bark-Lynn LEW ; Chan Ho NA ; Chang Ook PARK ; Chun Wook PARK ; Kui Young PARK ; Kun PARK ; Young Lip PARK ; Joo Young ROH ; Young-Joon SEO ; Min Kyung SHIN ; Sujin LEE ; Sang Hyun CHO
Annals of Dermatology 2023;35(1):86-87
8.A Case of Generalized Xerotic Eczema in a Patient with Congenital Insensitivity to Pain with Anhidrosis
Eun Ji HONG ; Hee Jung YOON ; Sul Hee LEE ; Young Lip PARK ; SangHoon LEE
Annals of Dermatology 2023;35(Suppl2):S191-S194
Congenital insensitivity to pain with anhidrosis (CIPA) is an extremely rare disease characterized by insensitivity to pain, anhidrosis, and intellectual disability. CIPA is caused by a genetic mutation in the neurotrophic tyrosine receptor kinase 1 (NTRK1) gene on chromosome 1. The anhidrosis leads to cutaneous changes such as skin dryness, lichenification, and impetiginization. Moreover, patients with CIPA may experience repeated trauma and recalcitrant eczema due to excessive scratching of wounds on their skin, because they do not feel any pain. Severe whole-body eczema in a patient with CIPA may be overlooked, leading these patients to be frequently diagnosed with atopic dermatitis and common eczema.Indeed, in patients with treatment-resistant or atypically distributed eczema and underlying anhidrosis, CIPA should be considered as a potential causative disease. Increased awareness of CIPA among dermatologists is necessary to ensure that patients receive an appropriate diagnosis. Herein, we report a rare case of generalized xerotic eczema in a patient with CIPA.
9.Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
Dong Hun LEE ; Hyun Chang KO ; Chan Ho NA ; Joo Young ROH ; Kui Young PARK ; Young Lip PARK ; Young Min PARK ; Chang Ook PARK ; Chun Wook PARK ; Youin BAE ; Young-Joon SEO ; Sang Wook SON ; Jiyoung AHN ; Hye Jung JUNG ; Jun-Mo YANG ; Chong Hyun WON ; Kwang Ho YOO ; Bark Lynn LEW ; Sang Eun LEE ; Sung Yul LEE ; Seung-Chul LEE ; Yang Won LEE ; Ji Hyun LEE ; Yong Hyun JANG ; Jiehyun JEON ; Tae-Young HAN ; Sang Hyun CHO
Annals of Dermatology 2022;34(2):157-160
10.Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea
Sang Wook SON ; Ji Hyun LEE ; Jiyoung AHN ; Sung Eun CHANG ; Eung Ho CHOI ; Tae Young HAN ; Yong Hyun JANG ; Hye One KIM ; Moon-Bum KIM ; You Chan KIM ; Hyun Chang KO ; Joo Yeon KO ; Sang Eun LEE ; Yang Won LEE ; Bark-Lynn LEW ; Chan Ho NA ; Chang Ook PARK ; Chun Wook PARK ; Kui Young PARK ; Kun PARK ; Young Lip PARK ; Joo Young ROH ; Young-Joon SEO ; Min Kyung SHIN ; Sujin LEE ; Sang Hyun CHO
Annals of Dermatology 2022;34(6):419-430
Background:
Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited.
Objective:
To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea.
Methods:
Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured.
Results:
Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7).The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30).Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt.
Conclusion
A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.

Result Analysis
Print
Save
E-mail